Phenture capital: Pharma and VC skill-swap to Build-A-Bio
This article was originally published in Scrip
Executive Summary
Big Pharma interest in accessing early-stage biotechnology is welcome news at a time when many venture capital firms are looking to invest their funds in later-stage technology. But the two increasingly are meeting in the middle, cooperating rather than competing to generate a return on investment, using complementary skill-sets to build innovative companies.